Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Jerome Fayette, Claire Cropet, Julien Gautier, Clemence Toullec, Mickael Burgy, Amandine Bruyas, Christian Sire, Aurelie Lagrange, Florian Clatot, Benoit Calderon, Marie Vinches, Mariana Iacob, Laurent Martin, Eve Marie Neidhardt Berard, Marie-Christine Kaminsky, Damien Vansteene, Sébastien Salas

J Clin Oncol 41, June 2023 (suppl; abstr 6003)

A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.

Caroline Even, Amaury Daste, Esma Saada-Bouzid, Gautier Lefebvre, Jerome Fayette, Sylvie Zanetta, Marie-Christine Kaminsky, Didier Cupissol, Alain Prevost, Elodie Vauleon, Alison Claire Johnson, Sebastien Salas, Frederic Rolland, Miruna Timar David, Isabelle Jallut, Jessy Delaye, Jean Bourhis, Joel Guigay, Matthieu Texier, Anne Auperin

J Clin Oncol 37, 2019 (suppl; abstr 6032)

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Joel Guigay, Jerome Fayette, Ricard Mesia, Cedrik Lafond, Esma Saada-Bouzid, Lionnel Geoffrois, Laurent Martin, Didier Cupissol, Olivier Capitain, Helene Castanie, Damien Vansteene, Philippe Schafhausen, Catherine Dubos Arvis, Caroline Even, Christian Sire, Melissa Delhommeau, Cecile Michel, Jean Bourhis, Ulrich Keilholz, Anne Auperin

J Clin Oncol 37, 2019 (suppl; abstr 6002)

Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study.

Mathilde Saint-Ghislain, Yungan Tao, Marc Alfonsi, Pierre Boisselier, Muriel Garcia-Ramirez, Claude Tuchais, Philippe Maingon, Christian Sire, Ali Hasbini, Marie Saliou, Cedrik Lafond, Hao Qiu, Sébastien Guihard, Pascal Garaud, marie-Helene Calais, Juliette Thariat, Laurent Martin, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6034)

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

Yungan Tao, Anne Auperin, Xu Shan Sun, Christian Sire, Laurent Martin, G Bera, Alexandre Coutte, Jessica Miroir, Cedrik Lafond, Natacha Colin-Batailhou, Aline Maillard, Laurent Gibel, Cécile Michel, Joel Guigay, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6076)

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Shan Sun, Christian Sire, Yungan Tao, Laurent Martin, Marc Alfonsi, Jean Briac Prevost, Michel Rives, Cedrik Lafond, Jean-Marc Tourani, Julian Biau, Lionnel Geoffrois, Alexandre Coutte, Xavier Liem, Elodie Vauleon, Franck Drouet, Jean-François Ramee, Gabriel Waksi, Laura Sinigaglia, Anne Auperin, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6018)